Altimmune to Announce Year End 2017 Financial Results on March 29
GAITHERSBURG, Md., March 20, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the quarter and year ended December 31, 2017 before the market open and host a conference call on Thursday, March 29.
| Conference Call Details | |||
| Date: | Thursday, March 29 | ||
| Time: | 8:30am Eastern Time | ||
| Domestic: | 866-548-4713 | ||
| International: | 323-794-2093 | ||
| Conference ID: | 6280732 | ||
| Webcast: | http://public.viavid.com/index.php?id=128569 | ||
| Replays, Available through April 12th: | |||
| Domestic: | 844-512-2921 | ||
| International: | 412-317-6671 | ||
| Replay PIN: | 6280732 | ||
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
Contacts:
Bill Enright
President and CEO
Phone: 240-654-1450
enright@altimmune.com
Ashley Robinson
LifeSci Advisors, LLC
617-535-7742
arr@lifesciadvisors.com